Xtant Medical Holdings, Inc. (XTNT) shareholders
XTNTNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026Score 9/3074% below fair value
$0.27−0.00 (-1.31%)
Close on Nov 13, 2026Market cap $38.12MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
149M of 140M shares
Institutional holders
32
5 new, 7 sold out
Net institutional buying
68M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Harkey Wilmot B. Joint filing with Nantahala Capital Management, LLC (49.10%), Mack Daniel (49.10%) and 1 more | 68,394,000 | 49.10% | 13D (active) amendment | Aug 1, 2025 |
| Nantahala Capital Management, LLC Joint filing with Wilmot B. Harkey (49.10%), Daniel Mack (49.10%) and 1 more | 68,394,000 | 49.10% | 13D (active) | Apr 10, 2025 |
| Daniel Mack Joint filing with Nantahala Capital Management, LLC (8.21%), Wilmot B. Harkey (8.21%) | 11,394,000 | 8.21% | 13G (passive) | Sep 30, 2024 |
| Laurence W. Lytton | 9,463,442 | 6.80% | 13G (passive) | Apr 15, 2025 |
| Altium Capital Management, LP | 8,027,593 | 6.20% | 13G (passive) amendment | Dec 31, 2023 |
| Lytton Laurence W Joint filing with Lytton-Kambara Foundation (5.00%) | 7,702,002 | 5.50% | 13G (passive) amendment | Dec 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of XTNT | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Nantahala Capital Management, LLC | 136,788,000 | 97.51% | $57.59M | +68,394,000 | 0.96% |
| AWM Investment Company, Inc. | 5,976,910 | 4.26% | $2.52M | – | 0.22% |
| Vanguard Capital Management LLC | 2,014,603 | 1.44% | $848.15K | – | 0.00% |
| Renaissance Technologies LLC | 935,119 | 0.67% | $393.69K | −52,291 | 0.00% |
| Geode Capital Management, LLC | 517,133 | 0.37% | $217.77K | −12,081 | 0.00% |
| Crescent Grove Advisors, LLC | 412,024 | 0.29% | $173.46K | – | 0.01% |
| Nano Cap New Millennium Growth Fund L P | 400,000 | 0.29% | $168.40K | +50,000 | 0.13% |
| Vanguard Fiduciary Trust Co | 257,988 | 0.18% | $108.61K | – | 0.00% |
| Citadel Advisors LLC | 191,369 | 0.14% | $80.57K | +30,358 | 0.00% |
| Acadian Asset Management LLC | 180,299 | 0.13% | $73.00K | – | 0.00% |
| Bridgeway Capital Management, LLC | 164,100 | 0.12% | $69.09K | – | 0.00% |
| Wiregrass Investment Management LLC | 150,000 | 0.11% | $63.15K | +47,000 | 0.04% |
| BlackRock, Inc. | 115,782 | 0.08% | $48.74K | – | 0.00% |
| Mink Brook Asset Management LLC | 109,466 | 0.08% | $46.09K | – | 0.02% |
| Northern Trust Corp | 101,127 | 0.07% | $42.57K | +1,529 | 0.00% |
| Millennium Management LLC | 84,490 | 0.06% | $35.57K | −47,864 | 0.00% |
| XTX Topco Ltd | 68,531 | 0.05% | $28.85K | +30,598 | 0.00% |
| UBS Group AG | 31,920 | 0.02% | $13.44K | New | 0.00% |
| State Street Corp | 31,266 | 0.02% | $13.16K | – | 0.00% |
| Sei Investments Co | 24,760 | 0.02% | $10.42K | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 32 | 149M | 100.0% | 5 / 7 | 3 / 7 | 69M | 1M |
| Q1 2026 | 34 | 81M | 57.6% | 6 / 6 | 6 / 6 | 3M | 1M |
| Q4 2025 | 35 | 81M | 58.0% | 12 / 4 | 9 / 7 | 2M | 0M |
| Q3 2025 | 30 | 80M | 57.1% | 4 / 8 | 5 / 4 | 0M | 0M |
| Q2 2025 | 30 | 80M | 57.0% | 6 / 7 | 6 / 4 | 64M | 81M |
| Q1 2025 | 28 | 96M | 68.7% | 3 / 3 | 7 / 5 | 0M | 1M |
| Q4 2024 | 30 | 97M | 68.9% | 7 / 5 | 8 / 5 | 0M | 2M |
| Q3 2024 | 28 | 98M | 70.0% | 3 / 7 | 5 / 1 | 5M | 0M |
| Q2 2024 | 27 | 94M | 66.8% | 2 / 7 | 11 / 8 | 5M | 2M |
| Q1 2024 | 33 | 90M | 64.4% | 6 / 11 | 8 / 4 | 1M | 5M |
| Q4 2023 | 31 | 94M | 67.1% | 5 / 15 | 4 / 2 | 5M | 1M |
| Q3 2023 | 28 | 90M | 64.4% | 11 / 12 | 4 / 2 | 9M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
6 funds held XTNT in Q2 2026, 78% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of XTNT | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,499,266 | 1.07% | $631.19K | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 515,337 | 0.37% | $216.96K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 241,904 | 0.17% | $111.76K | 0.00% | May 31, 2026 |
| Ultra-Small Company Market Fund | 154,100 | 0.11% | $64.88K | 0.04% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 113,093 | 0.08% | $52.25K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 74,213 | 0.05% | $34.29K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Sean E. Browne | President and CEO, Director | 3,114,669 | 2.22% | Aug 18, 2026 |
| Mark A. Schallenberger | Chief Operating Officer | 1,106,087 | 0.79% | Aug 18, 2026 |
| Scott C. Neils | CFO and Assistant Secretary | 1,243,381 | 0.89% | Aug 18, 2026 |
| Abhinav Jain | Director | 373,745 | 0.27% | Aug 18, 2026 |
| John K. Bakewell | Director | 1,129,633 | 0.81% | Aug 18, 2026 |
| Stavros G. Vizirgianakis | Director | 7,838,845 | 5.59% | Aug 18, 2026 |
| Jonn R. Beeson | Director | 1,748,408 | 1.25% | Aug 18, 2026 |
| Tyler Lipschultz | Director | 373,745 | 0.27% | Aug 18, 2026 |
| Capital Partners Limited Partnership Nantahala | 10% owner | – | – | Apr 17, 2025 |
| Daniel Mack | 10% owner | – | – | Apr 17, 2025 |
| Wilmot B. Harkey | 10% owner | 68,394,000 | 48.75% | Apr 17, 2025 |
| Nantahala Capital Management, LLC | 10% owner | – | – | Apr 17, 2025 |
| ROF II LLC Orbimed | 10% owner | 0 | – | Apr 14, 2025 |
| Advisors Llc Orbimed | 10% owner | 215,415 | 0.15% | Apr 14, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| John K. Bakewell Director | Aug 15, 2026 | Award | +215,517 | – | – | 1,129,633 |
| Mark A. Schallenberger Chief Operating Officer | Aug 15, 2026 | Tax withholding | −7,070 | $0.31 | $2.19K | 1,106,087 |
| Mark A. Schallenberger Chief Operating Officer | Aug 15, 2026 | Award | +450,000 | – | – | 1,113,157 |
| Jonn R. Beeson Director | Aug 15, 2026 | Award | +215,517 | – | – | 733,136 |
| Stavros G. Vizirgianakis Director | Aug 15, 2026 | Award | +323,275 | – | – | 7,838,845 |
| Scott C. Neils CFO and Assistant Secretary | Aug 15, 2026 | Award | +400,000 | – | – | 1,243,381 |
| Scott C. Neils CFO and Assistant Secretary | Aug 15, 2026 | Tax withholding | −28,155 | $0.31 | $8.73K | 1,215,226 |
| Sean E. Browne President and CEO, Director | Aug 15, 2026 | Tax withholding | −10,605 | $0.31 | $3.29K | 3,114,669 |
| Sean E. Browne President and CEO, Director | Aug 15, 2026 | Award | +550,000 | – | – | 3,125,274 |
| Abhinav Jain Director | Aug 15, 2026 | Award | +215,517 | – | – | 373,745 |
| Tyler Lipschultz Director | Aug 15, 2026 | Award | +215,517 | – | – | 373,745 |
| Mark A. Schallenberger Chief Operating Officer | Feb 15, 2026 | Tax withholding | −7,709 | $0.58 | $4.47K | 663,157 |
| Scott C. Neils CFO and Assistant Secretary | Jan 15, 2026 | Tax withholding | −8,084 | $0.65 | $5.25K | 843,381 |
| Scott C. Neils CFO and Assistant Secretary | Nov 15, 2025 | Award | +263,291 | – | – | 851,465 |
| Stavros G. Vizirgianakis Director | Nov 15, 2025 | Award | +553,797 | – | – | 7,515,570 |
| John K. Bakewell Director | Nov 15, 2025 | Award | +158,228 | – | – | 914,116 |
| Mark A. Schallenberger Chief Operating Officer | Nov 15, 2025 | Award | +292,253 | – | – | 670,866 |
| Jonn R. Beeson Director | Nov 15, 2025 | Award | +158,228 | – | – | 517,619 |
| Sean E. Browne President and CEO, Director | Nov 15, 2025 | Award | +394,937 | – | – | 2,575,274 |
| Tyler Lipschultz Director | Nov 15, 2025 | Award | +158,228 | – | – | 158,228 |
| John K. Bakewell Director | Nov 15, 2025 | Award | +158,228 | – | – | 158,228 |
| Abhinav Jain Director | Nov 15, 2025 | Award | +158,228 | – | – | 158,228 |
| Scott C. Neils CFO | Aug 15, 2025 | Tax withholding | −34,131 | $0.63 | $21.50K | 588,174 |
| Sean E. Browne President and CEO, Director | Aug 15, 2025 | Tax withholding | −10,605 | $0.63 | $6.68K | 2,180,337 |
| ROF II LLC Orbimed 10% owner | Apr 10, 2025 | Sale | −56,004,974 | $0.42 | $23.52M | 0 |
| ROF II LLC Orbimed 10% owner | Apr 10, 2025 | Sale | −17,109,618 | $0.42 | $7.19M | 0 |
| Scott C. Neils Chief Financial Officer | Jan 15, 2025 | Tax withholding | −7,986 | $0.53 | $4.23K | 622,305 |
| Sean E. Browne President and CEO, Director | Oct 15, 2024 | Tax withholding | −105,442 | $0.59 | $62.21K | 2,190,942 |
| John K. Bakewell Director | Aug 15, 2024 | Award | +162,162 | – | – | 755,888 |
| Stavros G. Vizirgianakis Director | Aug 15, 2024 | Award | +243,243 | – | – | 6,456,368 |
| Stavros G. Vizirgianakis Director | Aug 15, 2024 | Award | +505,405 | – | – | 6,961,773 |
| Sean E. Browne President and CEO, Director | Aug 15, 2024 | Tax withholding | −10,606 | $0.60 | $6.36K | 2,296,384 |
| Lori D. Mitchell-Keller Director | Aug 15, 2024 | Award | +162,162 | – | – | 353,124 |
| Jonn R. Beeson Director | Aug 15, 2024 | Award | +162,162 | – | – | 359,391 |
| Robert McNamara Director | Aug 15, 2024 | Award | +162,162 | – | – | 754,151 |
| Scott C. Neils Chief Financial Officer | Aug 15, 2024 | Tax withholding | −34,132 | $0.60 | $20.48K | 630,291 |
| Kevin D. Brandt Chief Commercial Officer | Aug 15, 2024 | Tax withholding | −56,333 | $0.60 | $33.80K | 943,736 |
| Mark A. Schallenberger Chief Operations Officer | Apr 3, 2024 | Award | +173,469 | – | – | 378,613 |
| Scott C. Neils Chief Financial Officer | Apr 3, 2024 | Award | +177,551 | – | – | 664,423 |
| Mark A. Schallenberger Chief Operations Officer | Apr 3, 2024 | Award | +177,551 | – | – | 382,695 |
| Sean E. Browne President and CEO, Director | Apr 3, 2024 | Award | +731,632 | – | – | 2,306,990 |
| Kevin D. Brandt Chief Commercial Officer | Apr 3, 2024 | Award | +184,209 | – | – | 1,000,069 |
| Scott C. Neils Chief Financial Officer | Jan 16, 2024 | Tax withholding | −7,986 | $1.09 | $8.70K | 486,872 |
| Kevin D. Brandt Chief Commercial Officer | Nov 17, 2023 | Buy | +41,670 | $1.20 | $50.00K | 815,860 |
| Sean E. Browne President and CEO, Director | Oct 15, 2023 | Tax withholding | −105,442 | $1.08 | $113.88K | 1,575,358 |
| Sean E. Browne President and CEO, Director | Oct 15, 2023 | Tax withholding | −111,721 | $1.08 | $120.66K | 1,569,079 |
| John K. Bakewell Director | Aug 15, 2023 | Award | +145,180 | – | – | 593,726 |
| Stavros G. Vizirgianakis Director | Aug 15, 2023 | Award | +217,770 | – | – | 6,213,125 |
| Mark A. Schallenberger Chief Operations Officer | Aug 15, 2023 | Award | +116,144 | – | – | 205,144 |
| Kevin D. Brandt Chief Commercial Officer | Aug 15, 2023 | Tax withholding | −49,880 | $1.18 | $58.86K | 774,190 |
| Kevin D. Brandt Chief Commercial Officer | Aug 15, 2023 | Award | +120,499 | – | – | 824,070 |
| Scott C. Neils Chief Financial Officer | Aug 15, 2023 | Tax withholding | −25,246 | $1.18 | $29.79K | 494,858 |
| Scott C. Neils Chief Financial Officer | Aug 15, 2023 | Award | +116,144 | – | – | 520,104 |
| Jonn R. Beeson Director | Aug 15, 2023 | Award | +145,180 | – | – | 197,229 |
| Sean E. Browne President and CEO, Director | Aug 15, 2023 | Award | +174,216 | – | – | 1,680,800 |
| Lori D. Mitchell-Keller Director | Aug 15, 2023 | Award | +145,180 | – | – | 190,962 |
| Robert McNamara Director | Aug 15, 2023 | Award | +145,180 | – | – | 591,989 |
| Lori D. Mitchell-Keller Director | Jun 15, 2023 | Award | +45,782 | – | – | 45,782 |
| Jonn R. Beeson Director | May 15, 2023 | Award | +52,049 | – | – | 52,049 |
| Mark A. Schallenberger Chief Operations Officer | Feb 15, 2023 | Award | +89,000 | – | – | 89,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of shares outstanding
0.27%
0M shares short
Days to cover
3.9
At 0M shares a day
Change since last report
+24.9%
From 0M shares
Short volume, 20 days
33.9%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Xtant Medical's stock actually held short. Settlement fails (shares not delivered on time) peaked at 208,644 shares on Aug 31, 2026 over the last 90 days.
See a number that looks wrong?